Loading...
•
Jun 30, 2020
Ironwood Pharmaceuticals Q2 2020 Earnings Report
Reported GAAP net income and grew LINZESS total prescription demand.
Key Takeaways
Ironwood Pharmaceuticals reported a solid quarter with GAAP net income of $25 million and adjusted EBITDA of $33 million. LINZESS total prescription demand grew by 9% year-over-year.
Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
Grew LINZESS® (Iinaclotide) total prescription demand by 9% year-over-year
New-to-brand prescription demand grew >15% in June 2020 compared to March 2020
Reinstating full year 2020 total revenue and LINZESS net sales growth guidance; reiterating adjusted EBITDA guidance
Forward Guidance
Ironwood is reinstating full year 2020 total revenue and LINZESS net sales growth guidance and reiterating adjusted EBITDA guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...